These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 28778292)

  • 21. Critically ill and septic patient: is red blood cell transfusion adding to the Domino Effect?
    Watkins TC; Clark CT
    J Infus Nurs; 2013; 36(2):116-21. PubMed ID: 23455973
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diminished bacterial clearance is associated with decreased IL-12 and interferon-gamma production but a sustained proinflammatory response in a murine model of postseptic immunosuppression.
    Murphey ED; Lin CY; McGuire RW; Toliver-Kinsky T; Herndon DN; Sherwood ER
    Shock; 2004 May; 21(5):415-25. PubMed ID: 15087817
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immune response and cytokines in septic rats undergoing blood transfusion.
    Salinas JC; Cabezali R; Torcal J; Larrad L; Sousa R; Navarro M; Lozano R
    J Surg Res; 1998 Dec; 80(2):295-9. PubMed ID: 9878327
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Pathophysiology and pathogens of sepsis].
    Hauber HP; Zabel P
    Internist (Berl); 2009 Jul; 50(7):779-80, 782-4, 786-7. PubMed ID: 19436978
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sepsis-Induced Immunosuppression in Neonates.
    Hibbert JE; Currie A; Strunk T
    Front Pediatr; 2018; 6():357. PubMed ID: 30555806
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TSLP induces a proinflammatory phenotype in circulating innate cells and predicts prognosis in sepsis patients.
    Qichuan Y; Li Y; Wang H; Xiong H
    FEBS Open Bio; 2019 Dec; 9(12):2137-2148. PubMed ID: 31628890
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunomodulation in sepsis: state of the art and future perspective.
    Antonopoulou A; Giamarellos-Bourboulis EJ
    Immunotherapy; 2011 Jan; 3(1):117-28. PubMed ID: 21174562
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Single versus combined immunoregulatory approach using PD-1 and CTLA-4 modulators in controlling sepsis.
    Rudick CP; Cornell DL; Agrawal DK
    Expert Rev Clin Immunol; 2017 Sep; 13(9):907-919. PubMed ID: 28742984
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systematic investigation on the turning point of over-inflammation to immunosuppression in CLP mice model and their characteristics.
    Deng D; Li X; Liu C; Zhai Z; Li B; Kuang M; Li P; Shang S; Song Y; Cen Y; Qin R; Lu Y; Zhao Y; Cheng H; Zheng J; Zhou H
    Int Immunopharmacol; 2017 Jan; 42():49-58. PubMed ID: 27875749
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Blood transfusion-related immunomodulation in patients with major obstetric haemorrhage.
    Jiao C; Zheng L
    Vox Sang; 2019 Nov; 114(8):861-868. PubMed ID: 31587289
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Markers of inflammation in sepsis.
    Takala A; Nupponen I; Kylänpää-Bäck ML; Repo H
    Ann Med; 2002; 34(7-8):614-23. PubMed ID: 12553502
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Pathophysiology of peritonitis].
    Beyer K; Menges P; Keßler W; Heidecke CD
    Chirurg; 2016 Jan; 87(1):5-12. PubMed ID: 26661744
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Myeloperoxidase instigates proinflammatory responses in a cecal ligation and puncture rat model of sepsis.
    Yu H; Liu Y; Wang M; Restrepo RJ; Wang D; Kalogeris TJ; Neumann WL; Ford DA; Korthuis RJ
    Am J Physiol Heart Circ Physiol; 2020 Sep; 319(3):H705-H721. PubMed ID: 32762560
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sepsis-induced immune dysfunction: can immune therapies reduce mortality?
    Delano MJ; Ward PA
    J Clin Invest; 2016 Jan; 126(1):23-31. PubMed ID: 26727230
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sepsis and Septic Shock: Lingering Questions.
    Dumont T; Francis-Frank L; Chong J; Balaan MR
    Crit Care Nurs Q; 2016; 39(1):3-13. PubMed ID: 26633153
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current insights in sepsis: from pathogenesis to new treatment targets.
    Wiersinga WJ
    Curr Opin Crit Care; 2011 Oct; 17(5):480-6. PubMed ID: 21900767
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Myeloid-Derived Suppressor Cells in Sepsis.
    Schrijver IT; Théroude C; Roger T
    Front Immunol; 2019; 10():327. PubMed ID: 30873175
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Deleterious clinical effects of transfusion-associated immunomodulation: fact or fiction?
    Vamvakas EC; Blajchman MA
    Blood; 2001 Mar; 97(5):1180-95. PubMed ID: 11222359
    [No Abstract]   [Full Text] [Related]  

  • 39. Potential Targets to Mitigate Trauma- or Sepsis-Induced Immune Suppression.
    Bergmann CB; Beckmann N; Salyer CE; Hanschen M; Crisologo PA; Caldwell CC
    Front Immunol; 2021; 12():622601. PubMed ID: 33717127
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Chinese expert consensus on diagnosis and management of immunosuppression in sepsis].
    Shock And Sepsis Society Of The Chinese Research Hospital Association ; Critical Care Medicine Society Of The Chinese People's Liberation Army (PLA) ; Critical Care Immunotherapy Research Group ; Wu J; Luan Y; Ke L
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2020 Nov; 32(11):1281-1289. PubMed ID: 33463483
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.